ABOS
Acumen Pharmaceuticals, Inc.
$1.98
-3.88%
2026-10-23
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Key Fundamentals
Forward P/E
-1.56
EPS (TTM)
$-1.64
ROE
-120.5%
Profit Margin
0.0%
Debt/Equity
55.26
Price/Book
2.83
Beta
0.38
Market Cap
$162.0M
Avg Volume (10D)
452K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$3.34
60D Low
$1.62
Avg Volume
461K
Latest Close
$1.98
Get breakout alerts for ABOS
Sign up for Breakout Scanner to receive daily notifications when ABOS triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Acumen Pharmaceuticals, Inc. (ABOS) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors ABOS daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. ABOS operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.